Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

2.7%

9 terminated/withdrawn out of 331 trials

Success Rate

79.5%

-7.0% vs industry average

Late-Stage Pipeline

13%

44 trials in Phase 3/4

Results Transparency

3%

1 of 35 completed trials have results

Key Signals

90 recruiting1 with results4 withdrawn

Enrollment Performance

Analytics

Phase 2
144(53.1%)
N/A
44(16.2%)
Phase 1
36(13.3%)
Phase 3
31(11.4%)
Phase 4
13(4.8%)
Early Phase 1
3(1.1%)
271Total
Phase 2(144)
N/A(44)
Phase 1(36)
Phase 3(31)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (331)

Showing 20 of 331 trials
NCT07629817Phase 3Not Yet Recruiting

Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

Role: lead

NCT07618546Not ApplicableNot Yet Recruiting

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Role: lead

NCT07610629Phase 2Not Yet Recruiting

Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer

Role: lead

NCT07002346Phase 3Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT07583888Phase 2Recruiting

VABu Conditioning in Elderly AML HSCT

Role: collaborator

NCT07559097Phase 1Recruiting

Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer

Role: lead

NCT07559786Phase 2Not Yet Recruiting

A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy

Role: lead

NCT04518475Phase 4Recruiting

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Role: collaborator

NCT07541001Phase 2Active Not Recruiting

PRL3-Zumab in Patients With Advanced Solid Tumors

Role: collaborator

NCT06140992Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Role: collaborator

NCT07540533Phase 2Recruiting

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

Role: lead

NCT05398861Phase 2Recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Role: lead

NCT04433156Phase 2Completed

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Role: lead

NCT04660097Phase 2Completed

Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Role: lead

NCT05769010Phase 2Recruiting

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Role: lead

NCT06328439Phase 1Active Not Recruiting

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT07492407Not Yet Recruiting

CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma

Role: lead

NCT07472621Not Yet Recruiting

Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Role: lead

NCT07459608Phase 2Not Yet Recruiting

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

Role: lead

NCT07442890Not ApplicableNot Yet Recruiting

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

Role: lead